Title: LegoChem’s
next-generation ADC technology Publication: Money
Today the Bell / Dong-Hee Kim Date: 4 July 2014 URL: link to website (contents
in Korean)
Summary
·
Antibody-drug conjugates (ADCs)
represent an innovative oncology therapeutic application that combines the
unique properties of monoclonal antibodies (mAbs) with the potent cell killing
activity of cytotoxic small molecule drugs. ·
LegoChem’s ADC proprietary technology
overcomes the limitation of the first generation ADCs, resulting in homogeneous
and safe ADCs. ·
LegoChem is preparing to enter into
the preclinical stage at the end of 2014 with its most advanced ADC pipeline,
and is working on licensing deals with global biotech/pharmas. ·
LegoChem’s Cephalosporin antibiotics
for gram-negative pathogenic bacteria shows great efficacy. The antibiotic
therapy of this class are still scarce but are in need considering the growing
number of patients with gram-negative infections. ·
LegoChem’s Oxazolidinone antibiotics
demonstrated efficacy non-inferior or superior to linezolid (Zyvox) and
superior safety parameters, especially with respect to myelosuppression. ·
LegoChem continues to execute on its
business model to partner with global biotech/pharmaceuticals to address and
solve the most important unmet medical needs of our time. About LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a
research-based biotechnology company dedicated to discovering, developing, and
commercializing innovative medicines by leveraging our chemistry expertise to
make conventional biologics targeted and more potent for the benefit of
patients with diseases of high unmet medical needs. We are advancing
sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants,
oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). | 
